Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Ionis Pharmaceuticals, Inc. (IONS) shares tumbled 23.5% to $64.65 as of July 9, 2026, a sharp decline from the prior close of $84.46. BestStocks flagged the session as a major change for IONS. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
IONS fell 23.5% to $64.65
Ionis Pharmaceuticals announced Thursday that its Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua), developed with partner AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, failed to meet its primary endpoint of reducing cardiovascular deaths and recurring heart problems (Reuters, Barron's). IONS fell 18.39% from $84.46 to $68.93 in intraday trading. Ionis and AstraZeneca's formal announcements regarding next steps for eplontersen (continued development, label modifications, or discontinuation) and any guidance updates on royalty expectations and pipeline priorities.
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Sharp 23.5% decline — elevated risk; High volume 8.0x on decline — distribution signal. Wall Street's consensus price target sits at $105.33, implying +62.9% upside from $64.65. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 27 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $64.65, down $19.81 (-23.45%) from the previous close of $84.46. The session traded on 8.0× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $64.65 and $86.33, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $105.33, 62.9% above the recent $64.65. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on IONS line up.
The bullish case
- Wall Street's consensus price target of $105.33 implies +62.9% upside from $64.65.
- The Street's most bullish target is $130.00 (+101.1%).
- Positive price momentum.
The bearish case
- Sharp 23.5% decline — elevated risk.
- High volume 8.0x on decline — distribution signal.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IONS
Frequently asked questions about IONS
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS tumbled 23.5% to $64.65. The move is tied to the catalyst and context summarized above, not unexplained technical trading.
How much did IONS stock fall?
IONS lost 23.45% ($19.81) versus the prior close of $84.46, last trading at $64.65 on 8.0× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-08-05 — about 27 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $105.33, about 62.9% above the current $64.65. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IONS-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.